22.418 articles found

MUCUNA PRURIENS AND EXTRACTS THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES

OLANOW WAREN C, VAN DER GIESSEN ROB, LEES ANDREW, WAGNER HILDEBERT.

· 2003-10-02

PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE

BERGREN MICHAEL S, HALSTEAD GORDON W, JU TZU-CHI R, CHAO ROBERT S, NIXON PHILLIP R, HAWLEY MICHAEL.

· 2003-10-02

Folate and homocysteine metabolism: therapeutic targets in cardiovascular and neurodegenerative disorders.

Mattson MP, Haberman F.

Curr Med Chem · 2003-10-01

DOI: 10.2174/0929867033456864PMID: 12871094

Oral L-dopa solution therapy of menstrual-related fluctuations in Parkinson's disease.

García-Moreno JM, Páramo L, Chacón J.

Parkinsonism Relat Disord · 2003-10-01

DOI: 10.1016/s1353-8020(03)00059-2PMID: 14499209

Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?

Lawrence AD, Evans AH, Lees AJ.

Lancet Neurol · 2003-10-01

DOI: 10.1016/s1474-4422(03)00529-5PMID: 14505581

First Parkinson gene therapy trial launches.

Howard K.

Nat Biotechnol · 2003-10-01

DOI: 10.1038/nbt879PMID: 14520380

Proteasome inhibition stabilizes tau inclusions in oligodendroglial cells that occur after treatment with okadaic acid.

Goldbaum O, Oppermann M, Handschuh M, Dabir D, Zhang B, Forman MS, Trojanowski JQ, Lee VM, Richter-Landsberg C.

J Neurosci · 2003-10-01

DOI: 10.1523/jneurosci.23-26-08872.2003PMID: 14523089

The interleukin-1 system: an attractive and viable therapeutic target in neurodegenerative disease.

Allan SM, Pinteaux E.

Curr Drug Targets CNS Neurol Disord · 2003-10-01

DOI: 10.2174/1568007033482742PMID: 14529361

Histamine H3 receptor: a potential drug target for the treatment of central nervous system disorders.

Alguacil LF, Pérez-García C.

Curr Drug Targets CNS Neurol Disord · 2003-10-01

DOI: 10.2174/1568007033482760PMID: 14529362

Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.

Lou JS, Kearns G, Benice T, Oken B, Sexton G, Nutt J.

Mov Disord · 2003-10-01

DOI: 10.1002/mds.10505PMID: 14534913

Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism.

Hill AN, Jankovic J, Vuong KD, Donovan D.

Mov Disord · 2003-10-01

DOI: 10.1002/mds.10554PMID: 14534926

Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease.

Baron MS, Dalton WB.

Mov Disord · 2003-10-01

DOI: 10.1002/mds.10551PMID: 14534933